BioStock: New CMO strengthens Lipum ahead of continued clinical development
Lipum is in the final stages of the clinical phase I study with SOL-116. In parallel, the company is preparing for the next step, a phase II study in rheumatoid arthritis. To strengthen its team for this, the company has recently recruited Karin Franck-Larsson as CMO. BioStock had the opportunity to interview Karin about her background and her expectations for her new role.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se